Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 465 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... May 9, 2022 Lucky 13-A Male Breast Cancer Story October 20, 2021 PRO Data Can Help When Deciding Between Neoadjuvant FOLFOX or Fluorouracil-Based... July 10, 2023 Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with... August 28, 2023 Load more HOT NEWS PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer Uncle Charlie’s Promise 10 Tips for National Cancer Prevention Month FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or...
